AUPH

Aurinia Pharmaceuticals Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website auriniapharma.com
Employees(FY) 300
ISIN CA05156V1022

Performance

-4.11%

-16.03%

+4.62%

+37.01%

-14.25%

YTD

+2.12%

Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Advanced Technical Analysis

Technical Analysis of AUPH 2025-01-31

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23 and the Technical Score at 26, both indicating weakness, while the Oscillators Score at 46 suggests a neutral stance. This combination implies a lack of strong bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AUPH

Stock Rank

Recent News & Updates

2025-01-31 08:38
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?(Zacks)
2025-01-22 12:00
Aurinia (AUPH) Upgraded to Buy: Here's Why(Zacks)
2024-12-11 13:03
Exploring Three High Growth Tech Stocks In The United States(Simply Wall St.)
2024-12-10 08:30
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options(Zacks)
2024-12-09 16:56
Aurinia Pharmaceuticals Insider Bought Shares Worth $10,822,000, According to a Recent SEC Filing(MT Newswires)
2024-12-06 09:54
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership(Simply Wall St.)
2024-11-18 17:53
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis(Business Wire)
2024-11-18 04:53
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis(Businesswire)
2024-11-15 06:00
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024(Business Wire)
2024-11-14 17:00
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024(Businesswire)
2024-11-14 06:00
Aurinia to Participate in Jefferies London Healthcare Conference(Business Wire)
2024-11-13 17:00
Aurinia to Participate in Jefferies London Healthcare Conference(Businesswire)
2024-11-11 08:32
RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating(MT Newswires)
2024-11-08 10:30
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets(Pharmaceutical Technology)
2024-11-08 06:37
Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring(TipRanks)
2024-11-08 02:12
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...(GuruFocus.com)
2024-11-07 10:41
Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise(MT Newswires)
2024-11-07 07:40
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates(Zacks)
2024-11-07 06:41
Aurinia: Q3 Earnings Snapshot(Associated Press Finance)
2024-11-07 06:10
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth(Business Wire)
2024-11-07 06:00
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development(Business Wire)
2024-11-06 17:10
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth(Businesswire)
2024-11-06 17:00
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development(Businesswire)
2024-11-02 10:36
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago(Simply Wall St.)
2024-10-30 16:05
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024(Business Wire)
2024-10-30 04:05
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024(Businesswire)
2024-10-29 18:00
Axonis Therapeutics Announces $115 Million Series A Financing(Prnewswire)
2024-10-11 06:00
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024(Business Wire)
2024-09-27 08:47
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability(Simply Wall St.)
2024-09-24 10:38
Aurinia Pharmaceuticals Says Lupus Nephritis Treatment Gets Japan's Approval(MT Newswires)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.